Retinoblastoma-associated pathway (Rb pathway) (Rb pathway)

The Retinoblastoma-associated pathway is a critical signaling network that regulates the transition of cells from the G1 phase to the S phase of the cell cycle (Source: Wikipedia, Retinoblastoma protein). At the center of this pathway is the Retinoblastoma protein (pRb), a tumor suppressor that inhibits cell cycle progression by binding to and sequestering E2F transcription factors (Source: UniProt, P06400). When cells receive growth signals, the Cyclin D-CDK4/6 complex phosphorylates pRb, leading to the release of E2F and the subsequent transcription of genes required for DNA synthesis (Source: StatPearls, Cell Cycle Control). Dysregulation of this pathway, often through RB1 gene mutations or overexpression of Cyclin D, is a hallmark of many human cancers, including retinoblastoma and breast cancer (Source: PubMed, PMC3741662). Therapeutic strategies often involve the use of CDK4/6 inhibitors, such as palbociclib and ribociclib, which prevent pRb phosphorylation and induce cell cycle arrest (Source: NIH, National Cancer Institute). These drugs have demonstrated significant clinical benefit in treating hormone receptor-positive, HER2-negative metastatic breast cancer (Source: FDA, Drug Approvals). Biomarkers such as RB1 status and p16 expression are frequently used to assess pathway integrity and predict response to these targeted therapies (Source: PubMed, PMC5812578).

Other names

Rb/E2F pathwayCyclin D-CDK4/6-INK4-Rb axispRb signaling pathwayRetinoblastoma signaling pathway

Inhibition of CDK4/6 kinases prevents the phosphorylation of the Retinoblastoma protein, maintaining it in an active state that sequesters E2F transcription factors and induces G1 cell cycle arrest.